Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Income Operating Income Growth	-143.9	-85.4	-52.42
Net Income Net Income Growth	-134.69	-74.88	-46.88
Earnings Per Share EPS Growth	-8.50	-10.04	-15.83
EPS Growth	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Cash & Investments Cash & Investments Growth	273.31	215.98	309.1
Total Debt Total Debt Growth	5.02	5.08	5.01
Net Cash (Debt) Net Cash Growth	268.29	210.9	304.09
Net Cash Growth	-	-30.65%	-
Net Cash Per Share Net Cash Per Share Growth	16.93	28.29	102.68

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024
Operating Cash Flow Operating Cash Flow Growth	-88.73	-77.94	-29.63
Capital Expenditures CapEx Growth	-0.03	-0.36	-0.11
Free Cash Flow Free Cash Flow Growth	-88.76	-78.3	-29.74
Free Cash Flow Growth	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 11, 2026

Data Sources Report a data error